跳至主要内容
临床试验/JPRN-UMIN000031615
JPRN-UMIN000031615尚未招募未知

Efficacy and safety of Glecaprevir/Pibrentasvir plus Ribavirin in Patients who failed Direct-acting antivirals; DAAs with chronic hepatitis C - Retreatment of Patients who failed DAAs with GLE/PIB+RBV

Tokai University0 个研究点目标入组 10 人开始时间: 2019年3月20日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
19years-old 至 85years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Decompensated cirrhosis(jaundice,refractory ascites,hepatic encephalopathy,esophageal varices,spontaneous bacterial peritonitis) 2) Child-Pugh >6 at screening 3) Patients during treatment regardless of any type of cancer 4) Pregnancy or possible pregnancy and breast feeding 5) Patients with severe heart disease 6) Patients with haemoglobinopathies 7) The patients who meets even one any of the following, neutrophils less than 750 /mm3, platelet counts less than <50000 /mm3, Hb less than 10 g/dl 8) Patients with impaired renal function with chronic kidney failure or creatinine clearance less than 50 ml/min 9) Patient with severe mental diseases such as severe depression, the suicide consideration 10)Patients who cannot keep 6-month contraception after in the dosage and the dosage in the male patients that a partner may become pregnant 11)Patients who was judged to be inappropriate

研究者

相似试验